Correction: Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia

Ítems similars

• Correction: Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia
  per: Jianing Wang, et al.
  Publicat: (2026-04-01)
• Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study
  per: Shida Pan, et al.
  Publicat: (2025-03-01)
• Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
  per: Yilin Wang, et al.
  Publicat: (2025-04-01)
• Early Alpha-Fetoprotein Response Predicts Sustained Tumor Response Following Immune Checkpoint Inhibitors Combined with Targeted Therapy in Liver Cancer
  per: Jiahe Tian, et al.
  Publicat: (2024-12-01)
• The Correlation Between Low Milk Supply in Breastfeeding and The Severity of Neonatal Hyperbilirubinemia
  per: Finanda Nisa Amani, et al.
  Publicat: (2026-02-01)